Melanotan II

—

evidence score

peptide

Research Only

MT-2Melanotan 2bremelanotide precursor+1 more

Melanotan II is a cyclic heptapeptide analogue of alpha-MSH (melanocyte-stimulating hormone) with potent agonism at MC1R (tanning), MC3R/MC4R (libido, appetite suppression, fat loss). It produces significant skin tanning without UV exposure, erection/arousal enhancement (bremelanotide/PT-141 was derived from it specifically for this effect), and appetite suppression. The original Melanotan I targeted only MC1R; Melanotan II is non-selective and hits all melanocortin receptors — producing a broader profile with more side effects. No FDA approval; RESEARCH ONLY status. Widely used in tanning and sexual enhancement communities. PT-141 (bremelanotide) is FDA-approved for female sexual dysfunction and derived from MT-II.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

0.5 mg

0.25 mgRange1 mg

Frequencydaily or every other day during loading; 2-3x/week maintenance

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~0.5-1 hour

OnsetLibido/arousal: 30-120 min; tanning: builds over multiple doses/1-2 weeks

DurationTanning effects persist for weeks post-cycle; acute libido effects 6-12 hours

Routes

subcutaneous_injection

intranasal

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Melanotan II is currently categorized as a peptide compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Non-selective melanocortin receptor agonist (MC1-4R); MC1R drives melanogenesis; MC3R/MC4R drive libido, appetite suppression, and pro-erectile pathways in hypothalamus

Practical Context

Strongest current signals

No indexed study summaries yet.